Are there antibody-drug conjugates approved for Small Bowel Cancer

Antibody-Drug Conjugates for Small Bowel Cancer

Based on the current NCCN Guidelines for Small Bowel Adenocarcinoma (Version 4.2025), there are no antibody-drug conjugates (ADCs) currently approved or recommended as standard treatment options for small bowel cancer.

What Are Antibody-Drug Conjugates?

An antibody-drug conjugate is a targeted therapy that combines:

• A monoclonal antibody (a protein that recognizes specific markers on cancer cells)
• A chemotherapy drug attached to it

This allows the chemotherapy to be delivered directly to cancer cells while sparing healthy tissue.

Why Aren't ADCs Standard for Small Bowel Cancer Yet?

Small bowel adenocarcinoma is a rare cancer, which means:

• Fewer patients are available for clinical trials
• Less research funding compared to common cancers
• Treatment guidelines are often extrapolated from colorectal cancer data rather than small bowel-specific studies

What IS Recommended Instead

According to the NCCN Guidelines, the standard first-line treatments for advanced small bowel cancer include:

Chemotherapy combinations:

• FOLFOX (5-FU, leucovorin, oxaliplatin)
• CAPEOX (capecitabine, oxaliplatin)
• FOLFIRINOX (5-FU, leucovorin, oxaliplatin, irinotecan)

Immunotherapy (if your tumor has specific genetic features):

• Checkpoint inhibitors like pembrolizumab or nivolumab for dMMR/MSI-H tumors

Important Note About HER2-Targeting

The NCCN Guidelines mention that HER2 alterations are more common in small bowel cancer compared to colorectal cancer. While trastuzumab deruxtecan (an HER2-targeting ADC) has shown promise in other cancers, the guidelines reference it only in the context of research and emerging data—not as a standard recommendation for small bowel cancer at this time.

Questions to Ask Your Oncologist

1. Has my tumor been tested for HER2 status or other targetable mutations?
2. Are there any clinical trials available for ADCs or other targeted therapies for my specific tumor profile?
3. Which first-line chemotherapy regimen do you recommend for my case?
4. Should I consider genetic testing to see if I'm eligible for immunotherapy?

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.